RT Journal Article
SR Electronic
T1 Plasma cell-free DNA promise disease monitoring and tissue injury assessment of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260139
DO 10.1101/2021.07.19.21260139
A1 Jin, Xin
A1 Wang, Yanqun
A1 Xu, Jinjin
A1 Li, Yimin
A1 Cheng, Fanjun
A1 Luo, Yuxue
A1 Zhou, Haibo
A1 Lin, Shanwen
A1 Xiao, Fei
A1 Zhang, Lu
A1 Lin, Yu
A1 Zhang, Zhaoyong
A1 Jin, Yan
A1 Zheng, Fang
A1 Chen, Wei
A1 Zhu, Airu
A1 Tao, Ye
A1 Zhao, Jingxian
A1 Kuo, Tingyou
A1 Li, Yuming
A1 Li, Lingguo
A1 Wen, Liyan
A1 Ou, Rijing
A1 Li, Fang
A1 Lin, Long
A1 Zhang, Yanjun
A1 Sun, Jing
A1 Yuan, Hao
A1 Zhuang, Zhen
A1 Sun, Haixi
A1 Chen, Zhao
A1 Li, Jie
A1 Zhuo, Jianfen
A1 Chen, Dongsheng
A1 Zhang, Shengnan
A1 Sun, Yuzhe
A1 Wei, Peilan
A1 Yuan, Jinwei
A1 Xu, Tian
A1 Yang, Huanming
A1 Wang, Jian
A1 Xu, Xun
A1 Zhong, Nanshan
A1 Xu, Yonghao
A1 Sun, Kun
A1 Zhao, Jincun
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260139.abstract
AB COVID-19 is a huge threat to global health. Due to the lack of definitive etiological therapeutics currently, effective disease monitoring is of high clinical value for better healthcare and management of the large number of COVID-19 patients. In this study, we recruited 37 COVID-19 patients, collected 176 blood samples upon diagnosis and during treatment, and analyzed cell-free DNA (cfDNA) in these samples. We report gross abnormalities in cfDNA of COVID-19 patients, including elevated GC content, altered molecule size and end motif patterns. More importantly, such cfDNA characteristics reflect patient-specific physiological conditions during treatment. Further analysis on tissue origin tracing of cfDNA reveals frequent tissue injuries in COVID-19 patients, which is supported by clinical diagnoses. Hence, we demonstrate the translational merit of cfDNA as valuable analyte for effective disease monitoring, as well as tissue injury assessment in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to thank Ms. Qi Wang from Shenzhen Bay Laboratory for her technical assistance. This study has been supported by China National GeneBank (CNGB), Shenzhen Bay Laboratory, National Key Research and Development Program of China (2018YFC1200100 to JZ), National Science and Technology Major Project (2018ZX10301403 to JZ), the emergency grants for prevention and control of SARS-CoV-2 of Ministries of Science and Technology, and Education of Guangdong province (2020A111128008, 2020B1111320003, 2020KZDZX1158 to JZ, and 2020B1111330001 to NZ), National Natural Science Foundation of China (32000398 to XJ), Natural Science Foundation of Guangdong Province, China (2017A030306026 to XJ), Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases (2019B121205005 to XJ), Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011 to XX), Guangdong Provincial Academician Workstation of BGI Synthetic Genomics (No. 2017B090904014 to HY), and BGI-research (BGIRSZ2020007 to KS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study had been approved by The First Affiliate Hospital of Guangzhou Medical University Ethics Committee, and the institutional review board of BGI; written informed consents had been obtained from all patients and healthy donor participated in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData access The data that support the findings of this study have been deposited into CNGB Sequence Archive (CNSA)(70) of China National GeneBank DataBase (CNGBdb) (71) with accession number CNP0001306. https://db.cngb.org/cnsa/project/CNP0001306/reviewlink/